Asked by: Rachel Blake (Labour (Co-op) - Cities of London and Westminster)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make it his policy to work with UKHSA to issue specific guidance for (a) health professionals and (b) the public regarding the health risks to pregnant people during periods of extreme heat.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department and the UK Health Security Agency (UKHSA) recognise that there are risks to pregnant women caused by exposure to extreme high temperatures which are set out in the Adverse Weather and Health Plan Equity Review and Impact Assessment 2024. This includes an assessment on stillbirth, pre-term birth, and maternal health complications.
UKHSA provides a weather-health alerting system for England, which alerts the public, including specific vulnerable groups such as pregnant women, and public sector organisations to prepare for impacts of adverse weather, including high temperatures. Risks to health are communicated via heat-health alerts.
There are no plans at this time to update National Health Service antenatal and maternity guidance or to publish specific guidance for healthcare professionals and the public regarding this topic.
Asked by: Mary Kelly Foy (Labour - City of Durham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with the Secretary of State for Science and Technology on the potential impact of a respiratory modern service framework on the life sciences ecosystem.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government will consider long-term conditions for future waves of modern service frameworks (MSFs), including respiratory conditions. The criteria for determining other conditions for future MSFs will be based on where there is potential for rapid and significant improvements in quality of care and productivity. After the initial wave of MSFs is complete, the National Quality Board will determine the conditions to prioritise for new MSFs as part of its work programme.
NHS England and the Department of Health and Social Care are working with the Department for Science, Innovation and Technology to explore innovation and policy opportunities in respiratory health.
Asked by: Kate Osamor (Labour (Co-op) - Edmonton and Winchmore Hill)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of proposed changes to the GP contract in England on (a) minoritised ethnic groups and (b) those with less visible and chronic conditions.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Department and NHS England assessed the potential impacts of the proposed changes to the GP Contract for 2026/27 throughout the policy-development process, including Equality Impact Assessments, which consider the impact of policy changes against protected characteristics, in line with the public sector equality duty. In relation to minoritised ethnic groups, the assessment found no evidence that the proposed changes would result in adverse impacts. The Department considers that several elements of the contract changes may support more equitable outcomes, including improvements to vaccination programmes and refinements to the Quality and Outcomes Framework (QOF), where uptake and disease prevalence are known to vary across different ethnic groups.
In relation to people with less visible and chronic conditions, we do not anticipate any adverse impact from the changes. Measures to improve access, continuity of care, and proactive management of long‑term conditions are expected to benefit patients with ongoing and complex health needs. In particular, the introduction of continuity of care as a core requirement will require practices and primary care networks to use risk‑stratification tools more systematically to target continuity where it is most beneficial, supporting more consistent clinical relationships, and better outcomes. The updated QOF requirements for long term and chronic conditions such as diabetes, heart failure, and obesity, align indicators with updated National Institute for Health and Care Excellence guidance, and support earlier intervention and preventative care to improve clinical outcomes for patients. In addition, clarifying expectations around not asking patients to call back another day, and clinically urgent and non‑urgent requests, will support timely management of requests, reduce repeat contacts, and will help to avoid any patients being left without appropriate follow-up.
The Department and NHS England will continue to monitor the impact of the GP Contract through workforce data, patient access metrics, and patient experience data, including demographic information collected through the GP Patient Survey, in order to identify and respond to any emerging differential impacts.
Asked by: Clive Efford (Labour - Eltham and Chislehurst)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps have been taken to address funding shortfalls and inequities between haemophilia centres around the UK, identified by 2024-25 peer review of haemophilia care.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.
The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.
In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.
The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.
The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.
Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.
In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.
Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.
Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.
As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.
Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.
Asked by: Clive Efford (Labour - Eltham and Chislehurst)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress he has made on establishing functioning multi-disciplinary networks to ensure best practice is followed in the treatment and care of haemophilia.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.
The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.
In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.
The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.
The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.
Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.
In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.
Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.
Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.
As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.
Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.
Asked by: Clive Efford (Labour - Eltham and Chislehurst)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what consideration he has given to supporting the National Haemophilia Database through additional central funding.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.
The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.
In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.
The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.
The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.
Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.
In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.
Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.
Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.
As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.
Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.
Asked by: Clive Efford (Labour - Eltham and Chislehurst)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps have been taken towards implementing Recommendation 9 of the Infected Blood Inquiry.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.
The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.
In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.
The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.
The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.
Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.
In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.
Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.
Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.
As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.
Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.
Asked by: Edward Morello (Liberal Democrat - West Dorset)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to engage people with Down Syndrome in policy development following the consultation entitled Down Syndrome Act 2022 draft statutory guidance, published on 5 November 2025.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Through the implementation of the Down Syndrome Act 2022, the Government is striving to improve life outcomes for people with Down syndrome, raise awareness and understanding of their needs, and break down barriers to opportunity that they, and other disabled people, face.
Under the Down Syndrome Act, my Rt Hon. Friend, the Secretary of State for Health and Social Care, is required to give guidance to relevant authorities in health, social care, education, and housing services on what they should be doing to meet the needs of people with Down syndrome. The Department engaged extensively with stakeholders, including people with lived experience of Down syndrome, to inform the development of the draft guidance, which was published for public consultation on 5 November 2025.
The consultation on the draft guidance closed on 30 March 2026. The Government will consider the responses received through the consultation to inform the final guidance to be published.
Asked by: Clive Efford (Labour - Eltham and Chislehurst)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress is being made in replacing plasma-derived products with recombinant coagulation factor products, where clinically appropriate, in accordance with Recommendation 9 of the Infected Blood Inquiry Report.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.
The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.
In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.
The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.
The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.
Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.
In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.
Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.
Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.
As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.
Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.
Asked by: Afzal Khan (Labour - Manchester Rusholme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the need to introduce transparency requirements for the funding of nutrition research.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research on health and social care through the National Institute for Health and Care Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health, including nutrition.
The Department is committed to funding research that has robust ethical oversight and independent governance. The NIHR ensures this by requiring studies, where appropriate, to gain approval from the Health Research Authority, which is responsible for overseeing ethical, governance, and legal aspects of research in England. Studies must also comply with the UK Policy Framework for Health and Social Care Research, which outlines the principles of good practice in the management and conduct of health and social care research in the United Kingdom.